PIK3CA testing in HR+/HER2- metastatic breast cancer: assessing pathology laboratories capacity and needs
{{output}}
The management of hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (MBC) relies on molecular testing to inform treatment decisions. PIK3CA mutations, present in ~40% of cases, represent a key predictive biomarker for PI3K-pathway-ta... ...
